Emerging studies suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , could offer a significant step forward for body loss . Preliminary clinical tests have indicated considerable reductions in visceral tissue, conceivably outperforming existing body composition treatments. Despite this, further evaluation is needed to completely